Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 11/20 | 0.42 |
| ▸ | HTR2C | P28335 | 11/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776374 | 0.89 | TSHR (0.46) | TSHRHTR2AHTR2CTP53POLB | |
| SCHEMBL16785583 | 0.85 | FAAH (0.38) | TP53GAASMN1; SMN2FAAH | |
| SCHEMBL16775910 | 0.81 | TSHR (0.48) | TSHRHTR2AHTR2CTP53POLB | |
| SCHEMBL16776371 | 0.80 | BRAF (0.38) | TSHRTP53GAASMN1; SMN2 | |
| SCHEMBL16776360 | 0.77 | HTR2C (0.46) | TSHRHTR2AHTR2CMAPTFAAH | |
| SCHEMBL16776380 | 0.77 | BRAF (0.46) | TP53POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL1815620 | 0.75 | HTR2C (0.49) | TSHRHTR2AHTR2CTP53GAA | |
| SCHEMBL16776375 | 0.74 | FAAH (0.38) | TP53GAASMN1; SMN2FAAH | |
| SCHEMBL12654217 | 0.74 | HTR2C (0.56) | TSHRHTR2AHTR2CTP53POLB | |
| SCHEMBL16776372 | 0.73 | CNR2 (0.51) | TP53GAASMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TSHR 3064/4885HTR2A 4386/4885HTR2C 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.